U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06794593) titled 'Effect Camostat for Kidney Protection in Chronic Kidney Disease' on Jan. 10.
Brief Summary: This clinical trial aims to evaluate the effects of Camostat Mesylate, a serine protease inhibitor, in patients with chronic kidney disease (CKD) and proteinuria. Proteinuria accelerates CKD progression and increases cardiovascular risks. By inhibiting serine protease activity and tubular complement activation, camostat may mitigate progressive kidney injury, potentially improving clinical outcomes.
This is an interventional, non-randomized, open-label pharmacodynamic trial that includes CKD patients with proteinuria and healthy controls. Th...